Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers

NCT02749903 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT02749903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02749903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 14, 2016
Completion date
July 5, 2028
Enrollment
46 (actual)
Sites
287

Conditions

As the registry lists them; a condition with its own page is linked.

androgen receptor positive, locally advanced salivary gland carcinoma, metastatic salivary gland carcinoma, salivary duct carcinoma, salivary gland adenocarcinoma, nos, salivary gland basal cell adenocarcinoma, stage iii major salivary gland cancer ajcc v7